Why is it astonishing when drug executives stay correct to their phrase? And can neoantigen cancer vaccines work?
We protect all that and far more this week on “The Readout LOUD,” STAT’s biotech podcast. Oruka Therapeutics CEO Lawrence Klein joins us to explore how his corporation raised its 1st round of financing just before competing with major gamers in the irritation room. We also talk about the newest information in the life sciences, together with the finish of the Amylyx ALS saga, yet another use scenario for GLP-1s, and a hurdle in Verve’s gene editing ideas.
Go through the rest…